ANZCTR search results

Anal fissure is a split in the lining of the back passage and is the source of intense pain on defaecation. The underlying cause is thought to be excessive contraction and poor blood flow in the muscle (anal sphincter) that is responsible for maintaining continence. Diltiazem hydrochloride, applied locally as a cream, reduces contractions and improves blood flow in the sphincter so helping to reduce pain on defaecation and increase the chances of healing of the fissure.

A trial of the efficacy of a Cognitivie Behavioral Therapy intervention delivered by post for problem cannabis use to reduce or eliminate cannabis use and reduce psychological disturbance where this is also a problem.

We conducted a trial in 103 de-novo chronic phase CML patients using imatinib 600 mg/day initially, increasing to 800 mg for suboptimal response. Ten patients not achieving major cytogenetic response (MCR) at 6 months and 13 with no complete cytogenetic response (CCR) at 9 months were eligible for dose increase, but this was only possible in 7/23 patients due mainly to non-hematologic toxicities. CCR was achieved in 90% and 95% of patients by 12 and 24 months, compared to rates of 69% and 80% in the IRIS trial. Major molecular response (MMR) was achieved in 47% and 72% of patients by 12 and 24 months compared to estimated frequencies of 40% and 55% in the IRIS trial. In the group averaging 600 mg throughout the first 12 months (n=51) 89% achieved MMR by 24 months compared to 50% in those averaging 500-599 mg in the first 6 months and 600mg in the second (n=18) (p=0.009). The superior molecular responses achieved in imatinib-treated patients who averaged 600 mg/day, compared to patients who were dose modified, suggest that early dose intensity of imatinib therapy may be critical to optimise response in CML.

The purpose of the study is to determine the efficacy and safety of a Mannatech product in improving quality of life and reducing fatigue in participants with diagnosed osteoarthritis of the knee. Participants will take 4 Mannatech preperations twice a day with food for 8 weeks, they will attend a clinic at baseline, week 4 and week 8. At these times they will complete the study questionnaires. Blood wil be taken at baseline and week 8 to determine safety parameters.

Exercise is a vital component of the physiotherapy management for young people with cystic fibrosis (CF). The overall aim of this research is to strengthen knowledge about best practice exercise programs for this population. This study compares effects of two exercise programs (the current exercise practice versus a novel targeted exercise program). Ultimately, it is expected that with improved exercise programs, young people with CF may have improved body structure and function, and activity and participation levels, leading to enhanced quality of life.

This trial will involve 6 healthy male volunteers to determine the pharmacokinetics and safety/tolerability of the investigational drug NV-27.

This is a study of the drug Dasatinib combined with chemotherapy for treating people with acute lymphoblastic leukaemia (cancer of bone marrow and white blood cells) who also have the Philadelphia Chromosome. Who is it for? You can join this study if you: - are aged 16–70 years - have the Philadelphia Chromosome - have acute lymphoblastic leukaemia which has not yet been treated. Trial details: All participants will receive Dasatinib tablets for 7 days prior to chemotherapy. Dasatinib will then be given at 50mg twice daily in combination with intensive chemotherapy using oral and intravenous drugs. Each course of Dasatinib plus chemotherapy lasts 14 days and a maximum of 8 courses will be given. Dasatinib is used to reduce the risk of relapse by killing cells with mutations that might otherwise be resistant to the more commonly used drug in this situation, called imatinib. The trial aims to assess the effectiveness, safety and tolerability of Dasatinib plus chemotherapy.

Background Over the last decade, there has been a significant shift in psychiatric services towards a greater focus on early intervention for psychotic illnesses. This has raised the question of what the most appropriate form of treatment is for people (very) early in the course of a first psychotic episode. It is also possible that due to the efforts of early detection programs, the composition of first episode psychosis (FEP) cohorts may have changed towards including those who may have a more benign course of psychotic symptoms and thus may respond to more benign treatments. Aims The purpose of this project is to investigate whether a sub-group of young people can recover from FEP with intensive psychosocial intervention but without taking antipsychotic medication. Although we know that antipsychotic medication is usually helpful in assisting recovery from psychosis, medication may not be essential for effective treatment in all cases. Furthermore, there is also evidence that psychological treatment is helpful and may be sufficient and more acceptable to young people who are experiencing FEP. Design Participants will be young people, aged 15 - 25 receiving treatment from the Early Psychosis Prevention and Intervention Centre (EPPIC) of ORYGEN Youth Health. Approximately 95 young people will be randomised to two treatment groups: 1. Medication (risperidone) plus intensive psychosocial treatment (MIPT) 2. Placebo plus intensive psychosocial treatment (PIPT) The trial will be of 6 months duration. Intensive contact with participants will be maintained by case managers and psychiatrists throughout this time. Clinical, neuropsychological and neuroimaging measures will be taken at baseline and at various follow-up points (3, 6, 12, 24 months). Outcomes The primary outcome of interest is functional and symptomatic outcome (at 6, 12 and 24 months) in each treatment group. Specifically, it is of interest whether participants in the PIPT group achieve similar levels of functional and symptomatic improvement compared to the MIPT group at short- and long-term follow-up. Another outcome of interest is the proportion of the PIPT group who are not placed on antipsychotic medication during the 6-month period. These participants will have achieved satisfactory remission without antipsychotic medication. This sub-group will be compared on functioning and symptom scales to those randomised to the medication group and to those for whom antipsychotic medication was commenced due to worsening mental state and/or risk. Characteristics of this group will be analysed to determine the sub-group of FEP patients who may achieve remission from symptoms without antipsychotic medication. A PhD project has been added that will recruit a healthy comparison group to examine changes in physical health and neuropsychological functioning over time in the study age group.

Physiotherapists are being used more often in Emergency Departments to help treat people with simple musculoskeletal injuries. The physiotherapist in the Emergency Department can treat directly (primary contact physiotherapy), or treat after the patient is first seen by a doctor who then refers on to physiotherapy (secondary contact physiotherapy). The aim of this project is to compare the different models of physiotherapy services for people with simple peripheral musculoskeletal injuries presenting to Emergency Departments. It is hypothesised that compared to secondary contact physiotherapy, primary contact physiotherapy will reduce length of stay in the Emergency Department, without having any adverse effects, such as an increased re-presentation rate.